Lifecare ASA

Environmental & Social Information • Aug 21, 2024

LIFE Successfully completed nine weeks of longevity trials

LIFE Successfully completed nine weeks of longevity trials

Bergen, Norway, 21 August 2024: Today, Lifecare ASA (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM), can announce positive results from nine weeks of sensor

longevity trials.

Reference is made to press releases 18 June 2024 when the company initiated

the trials with wireless readout. The Sencell sensor that has been implanted

under the skin of the dog Elli has now passed an operational lifetime of two

months and still counting. During these months, the Lifecare Veterinary team

located at the Norwegian University of Life Sciences (NMBU) has received large

amounts of data. This validates the functionality of the Sencell sensor and

the sensor technology itself.

The main purpose of the first sensor of the longevity trial is to investigate

and confirm operational lifetime in a longevity perspective. In this context,

the primary expectations of the study are to confirm the longevity of the

physical sensor properties, and that the sensor biocompatibility ensures that

no negative body reactions occur in a longevity perspective. The Team at

Lifecare Veterinary monitors the first pet-patient Elli on a daily basis,

including reports from her owner. Elli is in good health and shows no signs of

discomfort related to the implant.

- We are very excited to conclude two months of sensor longevity under Elli's

skin. The results from the study, which has been ongoing throughout the

summer, is in line with what we expected. However, it is very encouraging to

achieve the positive results of longevity in real-world settings. As we have

passed two months of operational lifetime, based on a wireless readout, we are

proud to conclude that the initial part of the longevity study is a success,

says CEO Joacim Holter at Lifecare.

- Previous in-vitro studies have confirmed sensor lifetime of six months. With

this initial conclusion of more than 9 weeks operational lifetime in vivo --

in real life settings -- we exceed the operational lifetime of all the major

CGM systems in the market with a factor of 4,5 or more. This is, of course,

interesting in a future commercial perspective, says Holter

- Alongside the initial part of the longevity study, we are preparing to

enroll additional patients in the study to confirm these first results, and to

intensify the study beyond sensor functionality, focusing sharper on glucose

readings from both healthy dogs and dogs with diabetes. With this approach we

expect to gain increased understanding of the sensor functionality in real

life conditions, says Managing Director Jo Amundstad at Lifecare Veterinary.

The approved study protocol allows us to implant the Sencell for a period of

12 weeks, after which it will be removed and specific studies on the potential

tissue impact will be evaluated. Due to the encouraging course of this initial

part of the study, we are currently in dialog with the regulatory authorities

to increase the implant period to 24 or more weeks before removal, says

Amundstad.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42